Integrin α7: a major driver and therapeutic target for glioblastoma malignancy
2017
Glioblastomas, or glioblastoma multiforme tumors (GBM), are aggressive high-grade malignant gliomas. They are the most frequent brain tumors in adults, corresponding to 12% to 15% of all intracranial tumors and 50% to 60% of astrocytic tumors (1). GBM are heterogeneous tumors caused by mutations in epidermal growth factor receptor ( EGFR ), isocitrate dehydrogenase ( IDH ) and platelet derived growth factor receptor alpha ( PDGFRA ) genes (1). Recent reports support the notion that GBM growth is mediated by stem cells [GBM stem cells (GSCs)] (2-4) that express neural stem cell markers (2) and can differentiate into pericytes and endothelial cells to support tumor vascularization (3,4). Different markers have been described for specific GSC sub-populations (2-4), but no common stem cell marker has been defined yet. Identification of GSC stem cell markers is critical for the development of new therapeutic targets for GBM.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
24
References
2
Citations
NaN
KQI